Lento Bio is developing small-molecule eyedrops that enhance lens flexibility to treat presbyopia, aiming to eliminate the need for corrective lenses. This approach directly addresses the loss of near vision associated with aging, providing a non-invasive alternative to traditional vision correction methods.
Funding
$5.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Presbyopia, the age-related loss of near vision, is caused by the stiffening of the eye's lens, making it difficult to focus on close objects. Current treatments primarily involve corrective lenses or surgery, which can be inconvenient or invasive. There is a need for a non-invasive therapeutic intervention that directly addresses the underlying cause of lens stiffening.
Solution
Lento Bio is developing small-molecule eye drops designed to restore lens flexibility and treat presbyopia. The eye drops target the accumulated damage in long-lived structural proteins within the lens, specifically advanced glycation end products (AGEs) that contribute to tissue stiffness. By inhibiting and reducing this damage, the therapeutic aims to rejuvenate the lens, improving its ability to focus and potentially eliminating the need for corrective lenses. The topical administration of the eye drops allows for high concentrations of the therapeutic agent to be delivered directly to the affected tissues, minimizing systemic exposure and potential toxicity.
Target Audience
The primary target audience includes individuals in their mid-40s and older experiencing presbyopia, as well as ophthalmologists and optometrists seeking non-invasive treatment options for their patients.
Features
- Small molecule therapeutics designed to penetrate deep into the lens tissue.
- Focus on inhibiting and reducing advanced glycation end products (AGEs).
- Topical administration via eye drops for direct delivery to the affected tissues.
- Aims to restore lens flexibility by targeting the underlying cause of age-related stiffening.